Advancing More Personalized Therapies for Rare & Common Kidney Diseases
March 17-19, 2025 | Boston, MA
Welcome to the Definitive Industry Focused Forum for Innovating Renal Drug Development
Advance More Personalized Therapies for Rare & Common Kidney Diseases
The transformative era of kidney drug development is here, with 2024 bringing landmark advancements, including Novartis’ Borealis Biosciences and approvals in IgAN, Travere Therapeutics, and industry-defining acquisitions by Biogen and Vertex. Breakthrough therapies like SGLT2 inhibitors, GLP-1s, and MRAs continue to reshape the CKD treatment paradigm, while the FDA’s accelerated pathways fuel unprecedented innovation. We are witnessing a renaissance in chronic kidney disease research and development and treatment.
The 7th CKD Drug Development Summit returns in 2025 as the definitive forum for connecting industry leaders, KOLs, researchers, and regulators. Addressing the most pressing challenges across renal research and development, this event serves as the unrivaled platform to share breakthroughs, inspire collaboration, and advance strategies for improving clinical outcomes in renal care all to bring better drugs to patients faster.
2025 Event Guide
What's On?
3 Track Conference
IgAN Nephrology Seminar Day
Deep-Dive Workshop Day
The flagship summit returned for its 6th iteration with an end-to-end program full of unrivalled scientific content across three tracks, perfect for all your teams:
- Discovery, pre-clinical & translational
- Proof of concept & early clinical
- Late clinical, regulatory & outcomes
The summit was dedicated to showcasing ground-breaking research into novel targets, pipeline breakthroughs and real-world patient studies with exclusive insights from Novartis, Calliditas, Genentech, Vera Therapeutics, Otsuka, Takeda, Travere and more.
The summit was specifically designed to address streamlining feasibility of pediatric CKD trials, validating the relevance of proteinuria and eGFR decline in diverse populations, and repositioning AKI at the forefront of R&D.
Scientific Poster Session
10+ Hours of Networking
60+ Expert Speakers
This allowed participants to showcase groundbreaking research, or understand what your peers have been working on. This was an opportunity to discover the latest innovations in the CKD space with no extra charge.
Networking allowed participants to forge valuable connections and reconnect with industry leaders through drinks receptions, speed networking sessions, lunch briefings, and more. You could have Joined over 200+ CKD experts from various sectors within the biopharma landscape.
This summit allowed for the sharing of cutting-edge pipeline updates, promising pediatric trial data and regulatory insights on the evolving landscape of acceptable surrogate endpoints.
2024 Speakers Included:
Dedicated Content Streams for 2024
Discovery, Preclinical & Translational
Early Clinical Innovation
Late Clinical, Regulatory & Outcomes
Participants:
- Navigated complex heterogeneity in CKD populations to identify more precise targets with Novo Nordisk and Maze Therapeutics
- Discovered more robust and human-relevant in vivo, ex vivo and in vitro kidney models to streamline translational progress with Pfizer, Eli Lilly, CSL Vifor and Janssen
- Leveraged GWAS, single-cell RNA sequencing, whole exome sequencing and more to discover CKD-specific pathways with Regeneron, University of Michigan and Novo Nordisk
Participants:
- Discovered novel prognostic biomarkers for CKD progression and transform proof of-concept studies with Alpine Immune Sciences, AstraZeneca, C-Path and HI-Bio
- Advanced knowledge of complement activation in glomerular diseases and evaluate the clinical potential of immunomodulatory candidates for CKD and renal transplantation with Novartis, Visterra and Alexion
- Uncovered recent clinical breakthroughs in regenerative medicine-based approaches to restore glomerular damage, podocyte injury and more with Purespring Therapeutics and Orbsen Therapeutics
Participants:
- Navigated clinical practice guidelines and design more efficient GFR decline studies in a rapidly evolving landscape of SGLT2s, GLP-1s and more with Otsuka, Bayer and Eli Lilly
- Explored innovation in surrogate endpoints, including a novel HCE for broad use across CKD trials with AstraZeneca, Veloxis Pharmaceuticals and University of Utah
- Strategically analyzed optimal avenues for reimbursement generation post-approval to maximize patient access in a competitive CKD market with HEOR Ltd and CSL Vifor
Attendees Included
Hear What Our Past Attendees Say
“One of the few events in the calendar which brings together such a large group of world leading experts in kidney drug development from multiple fields, fully focused and dedicated on how to improve the care for patients living with kidney disease.”
Dominik Steubl, Senior Clinical Program Leader, Boehringer Ingelheim
“The power of this Summit comes from both the diversity of topics and the diversity of subject matter experts across Industry, Academia, Health Care Authorities, and Patient Groups.”
Manish Maski, Head, Global Rare Nephrology Medical Affairs, Sanofi
“A one-of-a-kind unique blend of leaders in the Nephrology community, industry and science discussing exciting advances in biology and treatment of kidney diseases.”
Dermot Reilly, Director, Genetics & Translational Biology, Johnson & Johnson
Our 2024 Partners
Download Event Guide
Other Events in the Series
